Published in final edited form as:

Tetrahedron Lett. 2013 June 26; 54(26): . doi:10.1016/j.tetlet.2013.04.086.

Iterative Reducible Ligation to form Homogeneous Penicillamine Cross-linked Polypeptides

Mark D. Ericson and Kevin G. Rice*

Division of Medicinal & Natural Products Chemistry, College of Pharmacy, University of Iowa, Iowa City IA 52242

Abstract

The syntheses of homogeneous penicillamine disulfide cross-linked polypeptides are reported. Dodecapeptides containing N-terminal, C-terminal, or N- and C-terminal Pen were serially ligated into 36 amino acid polypeptides linked through Cys-Pen, Pen-Cys or Pen-Pen disulfide bonds. Critical to the syntheses was the incorporation of thiazolidine masked Cys and Pen as the N-terminal residues and selective hydrolysis with silver trifluoromethanesulfonate in acidic aqueous conditions to generate a free thiol for subsequent ligation. This approach allows the synthesis of homogeneous disulfide cross-linked polypeptides that have different reductive stabilities and have application in gene delivery by undergoing a tempered reductive triggered release of DNA.

Keywords

Reducible polypeptides; penicillamine; thiazolidine; gene delivery

Fundamental to the success of a gene delivery peptide or polymer is the ability to bind and protect plasmid DNA from serum nucleases.¹⁻³ The peptide-DNA polyplexes must be stable during systemic circulation to allow the polyplexes to concentrate in the desired cells, but disassemble after cellular uptake to permit transcription of the delivered plasmid. The assembly of multiple gene delivery peptides through disulfide bonds results in transiently stable reducible polypeptides. Disulfide bonds are relatively stable in serum but are readily cleaved upon entry into a cell due to the reducing environment created by high levels of glutathione.⁴ Several reports have demonstrated that reducible polypeptides mediate higher levels of gene expression compared to non-reducible systems.⁵⁻¹⁰ While higher expression was observed, the random polymerization of Cys-flanked peptides resulted in heterogeneous product mixtures that hindered the further optimization of the polypeptides. Only through the controlled ligation of individual peptides can the amount and location of each component peptide be optimized in the reducible polypeptide.

Recently we introduced a novel iterative reducible ligation methodology of generating homogeneous disulfide cross-linked polypeptides.¹¹ An N-terminal Cys residue was masked as an Fmoc-thiazolidine, which could be selectively converted to a free Cys in the presence of a disulfide bond without scrambling when silver trifluoromethanesulfonate was used to promote thiazolidine hydrolysis in acidic aqueous conditions. This method avoided the use

© 2013 Elsevier Ltd. All rights reserved.

*To Whom Correspondence Should be Addressed, Tel: 319-335-9903, Fax: 319-335-8766, kevin-rice@uiowa.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

of acetamidomethyl protected Cys previously reported for the generation of reducible polypeptides, permitting a milder synthesis avoiding the use of concentrated TFA and sulfonyl chlorides that may not permit stoichiometric deprotection of gene delivery peptides containing N-glycans and PEG.^{12–17}

In addition to optimizing the amount and location of each component within the polypeptide, the strength of the disulfide bonds is another parameter that can be optimized within a gene delivery polypeptide.^{7,18} Increasing the steric hindrance on the carbon bearing the sulfur increases the resistance of the disulfide bond to cleavage.^{19,20} Penicillamine (Pen), a Cys like amino acid with β,β -dimethyl substitution, can readily be incorporated into gene delivery peptides through solid phase peptide synthesis and has been shown to form more reductively stable disulfide bonds.^{21–24} Gene delivery polypeptides conjugated through disulfide bonds of differing strength may result in the tempered release of the DNA cargo. Endolytic fusogenic peptides that must function immediately upon cellular entry could be attached through readily cleavable Cys-Cys bonds, while other peptides such as nuclear localization signals could be linked through more stable Pen-Cys or Pen-Pen bonds to allow continued association with the plasmid DNA. Due to our previous success at generating homogeneous reducible polypeptides with thiazolidine mediated iterative reducible ligation and the prior use of thiazolidine masked penicillamines in peptide synthesis,^{25,26} we explored if a Pen could be incorporated to generate homogeneous polypeptides.

Here we report the synthesis of model polypeptides ligated through disulfide bonds while systemically replacing Cys with Pen (Figure 1). The synthesis of Cys containing polypeptide **1** has previously been reported;¹¹ this communication describes the chemistry to synthesize polypeptides containing N-terminal Pen (**2**), C-terminal Pen (**3**), and N- and C-terminal Pen (**4**).

The synthesis of N-terminal Pen polypeptide **2** was analogous to the previous report of the synthesis of **1** (Scheme 1). A donor peptide containing a free sulfhydryl N-terminal Pen (**5**) was ligated with 1.5 mol eq of an acceptor peptide activated as a S-2-sulfanylpuridine (**6**) to generate the polypeptide **7** containing a masked Pen as a Fmoc-5,5-dimethyl thiazolidine. Following preparative purification, **7** was recovered in 57 % yield. Removal of the Fmoc and thiazolidine hydrolysis was achieved using 5 v/v % piperidine/DMF for 5 min and 50 mol eq silver trifluoromethanesulfonate in 0.1 v/v % TFA for 1 hr respectively to generate the donor polypeptide **7a**. After each deprotection step, the intermediate was purified by gel filtration chromatography using Sephadex G-10 resin eluted with 0.1 v/v % TFA. After purification, donor polypeptide **7a** was immediately reacted with acceptor peptide **8** to generate the desired polypeptide **2** containing N-terminal Pen in 50 % preparative yield. These yields are comparable to the yields from the synthesis of **1**, reported as 49 % and 54 %.

The synthesis of C-terminal Pen polypeptide **3** required a minor modification of the synthetic protocol (Scheme 2). Initial attempts at activating a Pen sulfhydryl as an S-2-sulfanylpuridine or more reactive S-3-nitro-2-pyridylsulfenyl resulted in acceptor peptides with limited reactivity. Ten mol eq of a donor Cys peptide were required to form the mixed disulfide, similar to a previous report documenting the diminished reactivity of the 4-mercaptopyridine disulfide of Pen.²⁷ Due to the limited reactivity of these Pen products, the acceptor and donor peptides were inverted compared to the synthesis of **2** to maintain Pen on the donor peptide. Acceptor peptide **9** and donor peptide **10** were ligated, resulting in protected polypeptide **11** in 72 % yield. The same two-step deprotection unmasked the N-terminal Cys that was subsequently activated with dithiodipyridine to generate the acceptor polypeptide **11b**. Reaction with donor peptide **12** resulted in the desired polypeptide **3** in 45 % yield.

Extensive modification of the synthetic protocol was required in the generation of model polypeptide **4** (Scheme 3). Due to the limited reactivity of pyridylsulfenyl activated Pen and an observed propensity of unsubstituted Pen peptides to undergo homodimerization, an undirected oxidation of two Pen containing peptides was undertaken. To promote the formation of the heterodimer, peptide **5** was ligated with 10 mol eq of **13** in 100 mM ammonium acetate pH 5, generating the Pen-Pen disulfide polypeptide **14** purified in 72 % yield. The Fmoc was removed using 5 v/v % piperidine/DMF for 5 min as previously described, but lower amounts of AgOTf were required to prevent the premature breakdown of the Pen-Pen bond (10 mol eq versus 50 mol eq). The deprotected polypeptide was then reacted with Pen peptide **12** to generate the polypeptide **4** in 12 % yield containing 4 Pen conjugated through two disulfide bonds. RP-HPLC and ESI-MS analyses of all three final polypeptides products demonstrate their purity and mass (Figure 2). Mass-spectral characterization and yields for all peptides and polypeptides are reported in Table 1.

In summary, we demonstrated that thiazolidine mediated iterative reducible ligation is amendable to the incorporation of penicillamines to create more reductively stable disulfide bonds, especially if Cys-Pen mixed disulfides are desirable. Studies to improve the Pen-Pen disulfide bond reaction are ongoing to improve the synthetic yield and decrease the mol eq required for a directed reaction. The resulting methodology to incorporate Pen into gene delivery polypeptides is expected to generate polypeptides with greater control and sensitivity to the intracellular reducing environment and result in polyplexes that can be attenuated to release their DNA cargo, while retaining the desired the homogeneous products that can be systemically analyzed and optimized.

Acknowledgments

The authors gratefully acknowledge funding for this research by the NIH GM087653, T32 GM008365 and a predoctoral fellowship from the American Foundation for Pharmaceutical Education (MDE).

References

- Adami RC, Collard WT, Gupta SA, Kwok KY, Bonadio J, Rice KG. *J. Pharm. Sci.* 1998; 87:678–683. [PubMed: 9607943]
- Adami RC, Rice KG. *J. Pharm. Sci.* 1999; 88:739–746. [PubMed: 10430535]
- Chiou HC, Tangco MV, Levine SM, Robertson D, Kormis K, Wu CH, Wu GY. *Nucleic Acids Res.* 1994; 22:5439–5446. [PubMed: 7816636]
- Smith CV, Jones DP, Guenther TM, Lash LH, Lauterburg BH. *Toxicol. Appl. Pharmacol.* 1996; 140:1–12. [PubMed: 8806864]
- Chen CP, Kim JS, Liu DJ, Rettig GR, McAnuff MA, Martin ME, Rice KG. *Bioconjugate Chem.* 2007; 18:371–378.
- Chen CP, Kim JS, Steenblock E, Liu DJ, Rice KG. *Bioconjugate Chem.* 2006; 17:1057–1062.
- Kwok KY, Park Y, Yang YS, McKenzie DL, Liu YH, Rice KG. *J. Pharm. Sci.* 2003; 92:1174–1185. [PubMed: 12761807]
- Read ML, Bremner KH, Oupicky D, Green NK, Searle PF, Seymour LW. *J. Gene Med.* 2003; 5:232–245. [PubMed: 12666189]
- McKenzie DL, Smiley E, Kwok KY, Rice KG. *Bioconjugate Chem.* 2000; 11:901–909.
- McKenzie DL, Kwok KY, Rice KG. *J. Biol. Chem.* 2000; 275:9970–9977. [PubMed: 10744672]
- Ericson MD, Rice KG. *Biopolymers.* 2012; 98:510–517. [PubMed: 23203756]
- Futaki S, Ishikawa T, Niwa M, Yagami T, Kitagawa K. *Tetrahedron Lett.* 1996; 37:201–204.
- Futaki S, Kitagawa K. *Tetrahedron Lett.* 1994; 35:1267–1270.
- Futaki S, Kitagawa K. *Tetrahedron.* 1997; 53:7479–7492.
- Ottl J, Battistuta R, Pieper M, Tschesche H, Bode W, Kuhn K, Moroder L. *FEBS Lett.* 1996; 398:31–36. [PubMed: 8946948]

16. Ottl J, Moroder L. *Tetrahedron Lett.* 1999; 40:1487–1490.
17. Ottl J, Moroder L. *J. Am. Chem. Soc.* 1999; 121:653–661.
18. Sun W, Davis PB. *J. Controlled Release.* 2010; 146:118–127.
19. Kellogg BA, Garrett L, Kovtun Y, Lai KC, Leece B, Miller M, Payne G, Steeves R, Whiteman KR, Widdison W, Xie H, Singh R, Chari RVJ, Lambert JM, Lutz RJ. *Bioconjugate Chem.* 2011; 22:717–727.
20. Worrell NR, Cumber AJ, Parnell GD, Mirza A, Forrester JA, Ross WCJ. *Anti-Cancer Drug Des.* 1986; 1:179–188.
21. Drummer OH, Routley L, Christophidis N. *Biochem. Pharmacol.* 1987; 36:1197–1201. [PubMed: 3297070]
22. Joceyln, PCIn. *Biochemistry of the SH group: the occurrence, chemical properties, metabolism and biological function of thiols and disulphides.* London: Academic Press; 1972. p. 120
23. Parker AJ, Kharasch N. *Chem. Rev.* 1959; 59:583–628.
24. Rabenstein DL, Theriault Y. *Can. J. Chem.* 1984; 62:1672–1680.
25. King FE, Clarklewis JW, Smith GR, Wade R. *J. Chem. Soc.* 1959:2264–2266.
26. Sheehan, J.; Armstrong, W. *Abstracts of Papers; 122nd National Meeting American Chemical Society; Sept. 14–19, 1952; Atlantic City, NJ. p. p15MAbs. 23*
27. Greenfield L, Bloch W, Moreland M. *Bioconjugate Chem.* 1990; 1:400–410.

Figure 1. Polypeptides synthesized by thiazolidine mediated iterative reducible ligations. Polypeptide **1** contains N and C-terminal Cys, **2** contains N-terminal Pen and C-terminal Cys, **3** contains N-terminal Cys and C-terminal Pen, and **4** contains N and C-terminal Pen.

Figure 2.

Characterization of penicillamine containing polypeptides **2–4**. Panels A–C illustrate RP-HPLC analyses following injection of 2 nmol of peptide eluted with 0.1 v/v % TFA and an acetonitrile gradient of 5–55 % over 30 min while monitoring Abs_{280 nm}. The insets show the ESIMS for the product peaks. Panel A illustrates the re-analysis of preparatively purified **2** containing N-terminal penicillamines following iterative reducible ligation. Panel B illustrates the re-analysis of preparatively purified **3** containing C-terminal penicillamines. Panel C illustrates purified **4** following purification, containing two disulfide bonds composed of four penicillamines.

Scheme 1.

Synthesis of polypeptide **2**: (a) 100 mM ammonium acetate, pH 5; (b) i. 5 v/v % piperidine/DMF; ii. 50 mol eq AgOTf in 0.1 v/v % TFA.

Scheme 2.

Synthesis of polypeptide **3**: (a) 100 mM ammonium acetate, pH 5; (b) i. 5 v/v % piperidine/DMF; ii. 50 mol eq AgOTf in 0.1 v/v % TFA; iii. 10 mol eq DTDP in 10:3 2 M acetic acid:isopropanol.

Scheme 3.

Synthesis of polypeptide **4**: (a) 100 mM ammonium acetate, pH 5; (b) i. 5 v/v % piperidine/DMF; ii. 50 mol eq AgOTf in 0.1 v/v % TFA.

Table 1

Synthetic Yields and Mass Spectral Characterization of Peptides and Polypeptides

Peptide ^a	Mass (calc / obs)	% Yield
Fmoc-Lys(Acr)-(Lys) ₁₀ -Cys-OH/H-Pen-Trp-(Lys) ₉ -Cys-OH/H-Pen-Trp-(Lys) ₁₀ -OH (2)	5135.7 / 5134.4	50 ^b
Fmoc-Lys(Acr)-(Lys) ₁₀ -Pen-OH/H-Cys-Trp-(Lys) ₉ -Pen-OH/H-Cys-Trp-(Lys) ₁₀ -OH (3)	5135.7 / 5135.0	45 ^b
Fmoc-Lys(Acr)-(Lys) ₁₀ -Pen-OH/H-Pen-Trp-(Lys) ₉ -Pen-OH/H-Pen-Trp-(Lys) ₁₀ -OH (4)	5191.8 / 5191.5	12 ^b
H-Pen-Trp-(Lys) ₁₀ -OH (5)	1617.1 / 1616.8	26 ^c
Fmoc-Pen(Thz)-Trp-(Lys) ₉ -Cys(Pys)-OH (6)	1935.5 / 1935.4	52 ^c
Fmoc-Pen(Thz)-Trp-(Lys) ₉ -Cys-OH/H-Pen-Trp-(Lys) ₁₀ -OH (7)	3441.5 / 3441.0	57 ^b
Fmoc-Lys(Acr)-(Lys) ₁₀ -Cys(Pys)-OH (8)	2039.6 / 2039.2	42 ^c
H-Cys(Pys)-Trp-(Lys) ₁₀ -OH (9)	1698.2 / 1698.0	29 ^c
Fmoc-Thz-Trp-(Lys) ₉ -Pen-OH (10)	1826.4 / 1826.1	35 ^c
Fmoc-Thz-Trp-(Lys) ₉ -Pen-OH/H-Cys-Trp-(Lys) ₁₀ -OH (11)	3413.4 / 3412.6	72 ^b
Fmoc-Lys(Acr)-(Lys) ₁₀ -Pen-OH (12)	1958.6 / 1959.2	37 ^c
Fmoc-Pen(Thz)-Trp-(Lys) ₉ -Pen-OH (13)	1854.4 / 1854.5	43 ^c
Fmoc-Pen(Thz)-Trp-(Lys) ₉ -Pen-OH/H-Pen-Trp-(Lys) ₁₀ -OH (14)	3469.6 / 3469.6	72 ^b

^aThz refers to thiazolidine, Pen(Thz) to 5,5-dimethylthiazolidine, Pys to 2-sulfanylpipridine, and Lys(Acr) to Nε-acridinyllysine.

^bPurified yield determined for the last ligation step.

^cPurified yield based on initial resin substitution.